ID: ALA3347286

Max Phase: Preclinical

Molecular Formula: C203H325N51O65

Molecular Weight: 4520.12

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(C)=O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O

Standard InChI:  InChI=1S/C203H325N51O65/c1-14-106(8)165(251-191(307)128(53-29-39-93-212)227-174(290)124(49-25-35-89-208)230-197(313)149(101-164(283)284)250-195(311)147(99-114-103-219-119-44-20-18-42-117(114)119)248-190(306)140(69-82-161(277)278)236-183(299)135(64-77-156(267)268)239-194(310)146(221-111(13)256)98-113-102-218-118-43-19-17-41-116(113)118)201(317)244-142(71-84-163(281)282)186(302)238-139(68-81-160(275)276)189(305)247-145(97-112-55-57-115(257)58-56-112)199(315)254-168(110(12)255)203(319)242-127(52-28-38-92-211)176(292)228-129(54-30-40-94-213)192(308)252-166(107(9)15-2)202(318)243-141(70-83-162(279)280)185(301)237-138(67-80-159(273)274)188(304)246-144(96-105(6)7)198(314)253-167(108(10)16-3)200(316)241-126(51-27-37-91-210)175(291)224-121(46-22-32-86-205)171(287)220-109(11)170(286)223-132(61-74-153(261)262)180(296)233-133(62-75-154(263)264)181(297)232-131(60-73-151(215)259)179(295)231-130(59-72-150(214)258)178(294)226-123(48-24-34-88-207)173(289)225-125(50-26-36-90-209)177(293)249-148(100-152(216)260)196(312)240-136(65-78-157(269)270)184(300)234-134(63-76-155(265)266)182(298)235-137(66-79-158(271)272)187(303)245-143(95-104(4)5)193(309)229-122(47-23-33-87-206)172(288)222-120(169(217)285)45-21-31-85-204/h17-20,41-44,55-58,102-110,120-149,165-168,218-219,255,257H,14-16,21-40,45-54,59-101,204-213H2,1-13H3,(H2,214,258)(H2,215,259)(H2,216,260)(H2,217,285)(H,220,287)(H,221,256)(H,222,288)(H,223,286)(H,224,291)(H,225,289)(H,226,294)(H,227,290)(H,228,292)(H,229,309)(H,230,313)(H,231,295)(H,232,297)(H,233,296)(H,234,300)(H,235,298)(H,236,299)(H,237,301)(H,238,302)(H,239,310)(H,240,312)(H,241,316)(H,242,319)(H,243,318)(H,244,317)(H,245,303)(H,246,304)(H,247,305)(H,248,306)(H,249,293)(H,250,311)(H,251,307)(H,252,308)(H,253,314)(H,254,315)(H,261,262)(H,263,264)(H,265,266)(H,267,268)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)/t106-,107-,108-,109-,110+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,165-,166-,167-,168-/m0/s1

Standard InChI Key:  YVAUUQQRGDPCHF-HOGHYRSPSA-N

Associated Targets(non-human)

env Envelope glycoprotein gp160 (49 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Human immunodeficiency virus 1 (70413 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 4520.12Molecular Weight (Monoisotopic): 4517.3694AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Oishi S, Watanabe K, Ito S, Tanaka M, Nishikawa H, Ohno H, Shimane K, Izumi K, Sakagami Y, Kodama EN, Matsuoka M, Asai A, Fujii N.  (2010)  Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants,  (4): [10.1039/C0MD00091D]

Source